Clinical Trials Logo

Hepatitis, Autoimmune clinical trials

View clinical trials related to Hepatitis, Autoimmune.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04798625 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication

Nor-vaC
Start date: February 15, 2021
Phase:
Study type: Observational

The purpose of this study is to assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive and/or immunomodulating medication for immune-mediated inflammatory diseases in rheumatology and gastroenterology and after a liver transplantation.

NCT ID: NCT03217422 Active, not recruiting - Clinical trials for Autoimmune Hepatitis

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

AMBER
Start date: February 15, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

VAY736 dose testing; VAY736 efficacy and safety testing.

NCT ID: NCT02900443 Active, not recruiting - Clinical trials for Autoimmune Hepatitis

Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis

CAMARO
Start date: January 2017
Phase: Phase 4
Study type: Interventional

Rationale: Current standard therapy of autoimmune hepatitis consists of a combination of prednisolone and azathioprine. However, a significant proportion of patients does not respond to, or is intolerant for, azathioprine. Mycophenolate mofetil (MMF) has surpassed azathioprine as therapy to prevent organ transplant rejection and is sometimes used as an alternative option for autoimmune hepatitis. Several case series and one prospective study have documented the efficacy and safety of mycophenolate mofetil as induction therapy for autoimmune hepatitis. Robust evidence from a formal randomized clinical trial is lacking. Objective: To assess the efficacy and safety of mycophenolate mofetil as induction therapy in patients with treatment naive autoimmune hepatitis. Study design: Multicenter, randomised, open-label intervention study Study population: Patients with newly diagnosed autoimmune hepatitis who are in need of induction therapy according to current guidelines. Intervention: The intervention group will receive oral mycophenolate mofetil for 24 weeks. The control group will be treated with azathioprine for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent Clinical Practice Guidelines by the European Association for Study of the Liver (EASL). Main study parameters/endpoints: The primary outcome is the proportion of patients in biochemical remission, defined as normalization of serum alanine transaminase (ALT) and immunoglobulin G (IgG) levels after 24 weeks of treatment, per treatment group. Secondary endpoints include safety and tolerability of mycophenolate mofetil, time to remission, changes in Model For End-Stage Liver Disease (MELD) -score (and its components bilirubin, INR, creatinine), albumin, pseudocholinesterase and N-terminal procollagen-III-peptide, ELF (Enhanced Liver Fibrosis) -score and aspects of quality of life.